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Abstract
The taxanes are a class of chemotherapeutic agents that are widely used in the treatment of various
solid tumors. Although taxanes are highly effective in cancer treatment, their use is associated
with serious complications attributable to large interindividual variability in pharmacokinetics and
a narrow therapeutic window. Unpredictable toxicity occurrence necessitates close patient
monitoring while on therapy and adverse effects frequently require decreasing, delaying or even
discontinuing taxane treatment. Currently, taxane dosing is based primarily on body surface area,
ignoring other factors that are known to dictate variability in pharmacokinetics or outcome. This
article discusses three potential strategies for individualizing taxane treatment based on patient
information that can be collected before or during care. The clinical implementation of
pharmacogenetics, enzyme probes or therapeutic drug monitoring could enable clinicians to
personalize taxane treatment to enhance efficacy and/or limit toxicity.
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Taxanes are commonly used in the treatment of various solid tumors, such as breast cancer,
non-small-cell lung cancer and prostate cancer. They work by binding to the microtubule β-
tubulin subunit and interfering with microtubule depolymerization, which inhibits cell
division [1,2]. The first taxane, paclitaxel, was approved by the US FDA in 1992 [201],
followed by docetaxel 4 years later [202]. The search for improved formulations and new
taxanes has resulted in FDA approval of albumin-bound paclitaxel [3] and cabazitaxel [4],
and continues to this day [5,203].
Despite the initial success and continued optimization of taxanes, their use is associated with
serious limitations. Taxanes have a narrow therapeutic window and a broad adverse event
profile, of which hematopoietic and neurologic toxicities are most notable. Although the
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overall profiles are generally similar, the incidence of specific toxicities is quite different
between the two agents and the dose-limiting toxicities of paclitaxel and docetaxel,
neurotoxicity [6] and (febrile) neutropenia [7], respectively, are not the same.
Currently, taxane dosing is based primarily on body surface area (BSA) and in some cases
diminished liver function is considered [8,9]. Using this approach to initial dose selection,
large interindividual differences in pharmacokinetics (PK) are observed [10,11] and a
subpopulation of the treated population experiences severe, treatment-limiting adverse
events.
The taxanes are primarily eliminated via hepatic metabolism and biliary elimination (Figure
1) [12-14]. The proteins involved in hepatic uptake and intracellular metabolism influence
taxane PK and may have an indirect role in determining taxane outcome. Taxanes enter the
hepatocytes through rapid passive diffusion, due to their lipophilic character, and by
hepatocellular uptake by OATP1B3 [15,16]. Both taxanes are substrates for the highly
promiscuous CYP3A4/3A5 metabolic system [17,18], but the formation of paclitaxel
metabolites is also highly dependent on CYP2C8 activity [19]. The efflux proteins P-gp and
MRP2 are responsible for excreting taxanes and their metabolites into the bile [20-22].
Currently, there are no methods for identifying patients who are at high risk of toxicity
before treatment, thus all patients receiving taxanes need to be closely monitored by their
physician. In this article we will describe the use of three potential strategies
(pharmacogenetics, enzyme probes and therapeutic drug monitoring [TDM]), as tools to
individualize treatment with paclitaxel or docetaxel.
The germline genome may be a principal source of variability in drug PK or patient
susceptibility to adverse events. Discovery and validation of pharmacogenetic markers that
modify drug PK or patient sensitivity could enable appropriate drug or dose selection before
treatment initiation. A second approach to optimize initial dose selection is the use of
enzyme probes. Enzyme probes may be useful for estimating the patient’s metabolic activity
prior to treatment initiation, enabling selection of the optimal taxane starting dose for an
individual patient. The final approach, TDM, would allow clinicians to optimize taxane
doses during therapy. TDM is the systematic use of estimated drug exposure during previous
cycles to select ideal doses in subsequent cycles. In this article we will summarize the
rationale, describe preliminary attempts at implementation, discuss specific challenges to
clinical translation, and make recommendations for reasonable next steps in the
development of each of these three potential tools for individualizing taxane treatment.
Pharmacogenetics
Occurrence of adverse events and response to taxane treatment vary greatly among
individuals [10,11]. These interindividual differences are in part a result of differences in
drug exposure [23-25], but also reflect differences in patient sensitivity. Variation in the
patient’s germline genome is a major factor that influences drug exposure and patient
sensitivity. Genotyping specific SNPs can identify patients at elevated risk of adverse events
or lack of efficacy, enabling clinicians to make more informed decisions for patients being
treated with those chemotherapeutic agents [26]. Pharmacogenetics has been translated into
clinical practice to enable individualization of therapy with 6-mercaptopurine and irinotecan
based on TPMT [27] and UGT [28] polymorphisms, respectively. There may be individual
SNPs that are valuable pretreatment biomarkers to individualize taxane therapy; however,
no polymorphisms are currently being used to guide treatment decisions.
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Candidate SNPs in genes relevant to taxane PK
Early pharmacogenetic studies typically used a candidate gene approach in which the
investigator selects SNPs in genes that are likely to be important based on known biology of
the drug or phenotype of interest. Because paclitaxel and docetaxel have comparable
pharmacology and adverse event profiles it is likely that there is overlap between the
polymorphisms that influence treatment outcomes. A few studies have been published that
investigated the direct influence of SNPs on taxane PK, reporting inconsistent results
[29-36]. For example, Bergmann et al. [34] reported lower paclitaxel clearance in
individuals carrying the CYP2C8*3 variant and Fransson et al. [35] found a relationship
between ABCB1 2677G>T/A polymorphisms and decreased clearance of the 6α-
hydroxypaclitaxel metabolite. Henningsson et al. [33] and Marsh et al. [36] also investigated
the influence of these polymorphisms on paclitaxel PK, but could not reproduce these
findings.
At this time it is unclear whether there are any SNPs that could be useful for guiding taxane
treatment decisions because the pharmacogenetic literature is highly inconsistent. This issue
is caused by the frequent reporting of studies in small, heterogeneous cohorts of patients,
and the accepted practice of evaluating multiple SNPs and end points without appropriate
statistical correction. Thus, there is a high likelihood that published results reflect both false-
positive and false-negative findings. This section will not be a comprehensive review of all
SNPs or studies, we instead direct readers interested in that topic to previous reviews on
taxane pharmacogenetics [37,38]. In this section we will highlight SNPs that are most likely
to be associated with taxane treatment efficacy or toxicity based on multiple reports with
consistent findings. In order to maximize reader interpretability, all results will be described
as the effect of the variant compared with the wild-type genotype. An overview of
successfully replicated associations between polymorphisms and taxane outcomes is
displayed in Table 1.
CYP3A4 & CYP3A5—Both taxanes are substrates for the highly promiscuous
CYP3A4/3A5 metabolic system [17,18]. There is a strong linkage between the functional
CYP3A5*1 allele and CYP3A4*1B allele, and presence of these alleles together has been
related to increased docetaxel clearance [30,31]. A few studies have reported associations
between the low-activity CYP3A5*3 (6986A>G, rs776746) SNP and a lower risk of
hematological toxicity in patients treated with docetaxel [39] or paclitaxel [40], however, the
opposite finding has also been reported [41].
Paclitaxel is only partially metabolized by CYP3A4/3A5, so it is somewhat less likely that
this polymorphism will have adequate predictive power to be clinically useful in guiding
paclitaxel treatment decisions. Regardless, it is interesting that the low-activity CYP3A5*3
variant has been demonstrated to decrease neurotoxicity [42] and increase survival [43] in
paclitaxel-treated patients.
CYP2C8—Systemic elimination of paclitaxel occurs primarily by CYP2C8-mediated
hepatic metabolism [27]. Secondary analyses of three small studies [32,40,44] suggested an
increase in neurotoxicity risk of patients carrying the low-activity CYP2C8*3 variant, which
consists of two polymorphisms that occur in almost complete linkage disequilibrium
(416G>A, R139K, rs11572080; and 1196A>G, K399R, rs10509681). This has recently been
replicated in analyses of independent patient cohorts [42,45]. Hertz et al. also reported a
corresponding increase in neoadju-vant clinical complete response from 23 to 55% in breast
cancer patients who carried the *3 variant [44]. These reports of increased toxicity and
efficacy are consistent with the finding that patients carrying the *3 variant have 11% lower
paclitaxel clearance and, consequently, greater drug exposure [34].
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ABCB1—The ABCB1 gene encodes P-gp (also known as MDR1), expressed in the liver
and intestine. Three polymorphisms (3435C>T, I1145I rs1045642; 2677G>T/A, A893S/T,
rs2032582; and 1236C>T, G412G, rs1128503) in moderate linkage disequilibrium in the
ABCB1 gene have been extensively studied for an association with taxane treatment
outcomes, however, it is unclear which, if any, SNP is causing the observed effect on
outcome [46]. These three SNPs have been looked at as a haplotype, sometimes referred to
as ABCB1*2, as well as being studied individually. It was originally hypothesized that the
nonsynonymous triallelic (2677G>T/A) SNP is causative but more recent data suggest that
the two silent polymorphisms (3435C>T and 1236C>T) may alter protein function [47,48].
The ABCB1 variant alleles have been associated with a higher risk of neutropenia in
multiple studies with single-agent docetaxel [30,41,49]. In addition, an association between
an ABCB1 variant allele and a higher risk of hematological and gastrointestinal toxicities has
also been reported [50]. These findings correspond with the study of Bosch et al., in which
patients homozygous for the variant alleles had higher area under the curve (AUC) due to
decreased docetaxel elimination [29]. Consistent with their shared pharmacology, multiple
studies have reported an increase in hematological or gastrointestinal toxicities for
paclitaxel-treated patients carrying ABCB1 variants [50-53].
The three frequently studied polymorphisms in ABCB1 (3435C>T, 2677G>T/A and
1236C>T) have also been associated with taxane response or survival. The previously
mentioned study of Sissung et al. found that docetaxel-treated patients carrying variant
alleles had decreased overall survival (p = 0.0017) [49] and Pan et al. observed a poorer
response in these patients [54]. The association with efficacy of paclitaxel treatment is
somewhat less clear; ABCB1 variant alleles have been associated with shorter progression-
free survival, overall survival and lower disease control rates in Koreans [51,55], but greater
response rate [56,57] and progression-free survival [58] in other populations.
Other SNPs in genes relevant to taxane PK—Associations with taxane treatment
outcomes have been reported for other SNPs in a variety of transporters or phase II
metabolic enzymes, such as the hepatocellular uptake and efflux proteins OATP1B3 and
MRP2 [59]. The GST system has also been extensively investigated, but in most cases these
patients were treated with taxane–platinum combination therapy and the findings are most
likely relevant to the pharmacogenetics of the platinum compound [30,50,60-62].
Candidate SNPs in genes relevant to taxane pharmacodynamics
CYP1B1—CYP1B1 is an enzyme that is not expressed in normal tissue and does not
contribute to taxane PK, however, it has been detected in various tumors [63]. The *3
variant of the CYP1B1 enzyme (4326C>G, L432V, rs1056836) has shown increased
catalytic activity toward its substrates, including endogenous hormones such as 17β-
estradiol [64-66]. This altered enzyme activity may influence taxane efficacy by binding
directly to taxanes or producing an estrogen metabolite that antagonizes the taxane
mechanism of action [49,67], providing a plausible explanation for the multiple studies that
have demonstrated inferior survival or response to taxanes for patients carrying the
CYP1B1*3 genotype [36,68-70].
β-tubulin—Taxanes exert their cytotoxic effect by binding to β-tubulin in the cellular
microtubules. Recently, Leandro-García et al. identified two linked polymorphisms in the
proximal promoter of TUBB2A (-101T>C and -112A>G) that increase gene transcription.
Patients carrying these variants may be at decreased risk of developing paclitaxel-induced
neurotoxicity [71]. Similarly, a polymorphism in TUBB1 may modulate a patient’s risk of
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taxane-induced thrombocytopenia [72], however, replication of these associations has not
yet been attempted to our knowledge.
It is worth pointing out that β-tubulin somatic mutations have also been investigated for an
influence on paclitaxel response [73], however, the importance of these variations has been
controversial. The β-tubulin genes are known to be highly conserved across species [74] and
genotyping of this gene has been problematic owing to interference of β-tubulin
pseudogenes [75].
Other SNPs in genes involved in taxane pharmacodynamics—Testing the
hypothesis that taxane sensitivity may be related to the activity of proteins involved in the
repair of DNA damage, one study reported a significant association with a tagSNP in the
FANCD2 gene that increased gene expression and neuropathy risk [76]. This association
awaits replication in an independent patient cohort.
Genome-wide & noncandidate gene association studies
An alternative method for discovering polymorphisms that influence treatment outcome is
the genome-wide association study (GWAS). This approach enables the simultaneous
interrogation of a huge amount of the known genetic variation in humans. Baldwin et al.
published the first GWAS of a taxane clinical end point, reporting an association between an
FGD4 polymorphism and the onset of peripheral sensory neuropathy in a large paclitaxel-
treated discovery cohort and two independent replication cohorts [77]. This polymorphism
in FGD4 was found to increase the risk of neuropathy by 57% in the discovery cohort
(hazard ratio [HR]: 1.57; 95% CI: 1.30–1.91; p = 2.6 × 10-6) and an even larger increase in
risk was detected in independent cohorts of European (HR: 1.72; 95% CI: 1.06–2.80; p =
0.013) and African–American (HR: 1.93; 95% CI: 1.13–3.28; p = 6.7 × 10-3) patients.
FGD4 encodes for the protein Frabin, a widely expressed guanine nucleotide exchange
factor for Cdc42, a small rhoGTPases that regulates cellular morphogenesis, including
myelination. FGD4 has previously been linked with the congenital Charcot–Marie–Tooth
disease, a condition that resembles taxane-induced sensory peripheral neuropathy, providing
a plausible biological explanation for their finding. Other intriguing SNPs related to the
onset or severity of neuropathy in this study were found in EPHA5 (rs7349683) and FZD3
(rs10771973).
No GWAS of docetaxel outcomes has been published, however, one study used the
Affymetrix DMET 1.0 platform (Affymetrix Inc., CA, USA) to simultaneously interrogate
nearly 2000 variants in 225 genes that may be relevant to drug PK [78]. Interesting
associations of SNPs with docetaxel response (PPAR-δ, SLUT1C2 and CHST3) and toxicity
(SPG7, CHST3, CYP2D6, NAT2, ABCC6, ATP7A, CYP4B1 and SLC10A2) were reported,
however, replication of these findings has yet to be presented so it is unclear whether these
variants have a true effect on docetaxel treatment outcome.
Challenges of pharmacogenetics
The primary challenge to the field of pharmacogenetics at this time is the difficulty of
validating associations. Even the most highly studied and biologically reasonable effects,
such as the relationship between CYP2D6 genotype and tamoxifen outcomes, continue to be
debated in the literature [79]. Validation of pharmacogenetic associations requires carefully
planned studies in large, independent patient cohorts. After validation, prospective
genotype-guided studies are required to demonstrate a clinical benefit of modifying
treatment in patients who carry a specific SNP. This potential benefit will need to be
weighed against the additional cost of genotyping patients to identify potentially rare
variants of interest. Finally, variability in treatment outcome may be the result of the
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interplay of many genetic factors, including modifications in the epigenome or the
proteome. Thus, the explanatory value of any one SNP may be limited, and assessment of a
set of SNPs may be required to to guide taxane treatment decisions.
Future work for pharmacogenetics
Several associations have been reported between SNPs and taxane treatment outcomes,
although none have been consistently demonstrated in multiple independent cohorts to
warrant clinical implementation. Still, there are a few promising gene variants, such as the
polymorphisms in ABCB1, CYP2C8, CYP1B1, and FGD4, which based on the available data
should be prioritized for replication in large, independent, prospectively collected patient
cohorts. After replication, these markers should be tested in prospective, genotype-guided
studies to ascertain whether the clinical implementation of pharmacogenetics would improve
patient outcomes at a reasonable cost to the system. Finally, future work should seek to
understand the influence of dynamic changes upstream or downstream of the genome on the
static changes found within the genome.
Enzyme probes
Activity of metabolic enzymes is a major determinant of drug exposure. There are many
factors that could influence enzymatic activity for a given patient, such as drug interactions,
comorbidities, or genetic mutations. Instead of attempting to account for each factor
individually, it may be best to directly measure the metabolic activity for the patient using a
probe marker for the enzyme of interest. The ideal probe would measure enzyme activity in
a patient sample ex vivo, however, for taxane metabolism only in vivo probes have been
investigated. An ideal in vivo enzymatic probe is a safe, conveniently administered and
quickly interpretable marker agent that shares the metabolic pathway of the drug of interest,
enabling estimation of the expected rate of metabolism of the drug [80]. Use of a
pretreatment probe could help clinicians select a more appropriate dose in order to target a
desired level of exposure, potentially preventing toxicity or ineffectiveness.
The FDA maintains a list of substrates that can be used in drug development to measure in
vivo activity of the major CYP450 enzymes involved in drug metabolism, including
CYP2D6, CYP3A4, and CYP2C9 [204]. Currently, the use of enzyme probes in clinical
practice is limited; one example is the use of an enzyme probe to predict TPMT activity ex
vivo in patients who will receive thiopurine drugs. However, there could be many more
applications, particularly for CYP3A4, which is involved in the metabolism of the majority
of drugs used clinically. In this article we will refer to CYP3A because CYP3A4 and
CYP3A5 have highly overlapping substrate specificity [81], which makes it difficult to
determine their individual contribution to drug metabolism. CYP3A is involved in the
metabolism of both docetaxel and paclitaxel [82], and paclitaxel is also metabolized by
CYP2C8, therefore, this section will focus on the clinical translation of probes for CYP3A
and CYP2C8 activity.
Docetaxel probes
Erythromycin breath test—The erythromycin breath test (ERMBT) is a validated in
vivo assay for CYP3A activity that has been studied as a potential probe for docetaxel PK.
For this test 14C-labelled erythromycin is administered intravenously and the amount of 14C-
labelled CO2 exhaled is measured at specific time points, yielding an estimate of CYP3A
activity [83]. Several studies have reported a significant correlation between the ERMBT
and docetaxel clearance [31,84], with ERMBT explaining as much as 67% of the docetaxel
PK variability [85]. The utility of the ERMBT has also been demonstrated in groups of
patients in whom docetaxel dose selection is particularly challenging or would be
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particularly beneficial, such as the elderly [86] or patients with impaired liver function [87].
However, not all studies of the ERMBT were able to detect a significant correlation with
docetaxel PK [88].
Alternative probes for CYP3A activity—Several CYP3A probes other than the
ERMBT have been investigated for a relationship with docetaxel PK and toxicity (Table 2).
In the study from Michael et al., which did not detect an association with the ERMBT, the
clearance of anti-pyrine was correlated with docetaxel clearance (r2 = 79.49%; p = 0.007)
[88]. Dexamethasone plasma clearance has also been studied, though the correlation was
unexpectedly limited to females only [89,90]. The utility of midazolam plasma clearance as
a CYP3A probe is uncertain based on several conflicting reports [91-93]. Finally, the urinary
excretion of metabolites from exogenous cortisol has shown promise; a correlation between
urinary 6-β-hydroxycortisol (6-β-OHF) and docetaxel clearance has been reported (r =
0.867; p < 0.001) [94]. Yamamoto et al. published the first attempt to prospectively use an
enzyme probe to guide taxane dosing. In this study the docetaxel dose was selected based on
6-β-OHF, resulting in a significant decrease in docetaxel PK variability when compared with
standard BSA-based dosing [95]. Prospective validation of this approach makes a
compelling case for further research into the use of 6-β-OHF to guide docetaxel dosing to
improve therapeutic outcomes.
Paclitaxel probes
The use of a probe for paclitaxel dosing, as compared with docetaxel, is complicated by the
multiple routes of metabolism. The first attempt to predict paclitaxel clearance with a probe
was performed by Gréen and colleagues, who attempted to use quinidine as a CYP3A probe,
but no correlation was observed with paclitaxel clearance (Table 2) [32]. However, low
enzyme activity was correlated with high 6α-hydroxypaclitaxel AUC, the metabolite formed
by CYP2C8. This suggests that when CYP3A enzyme activity is diminished, CYP2C8 may
compensate by increasing its metabolism of paclitaxel.
Our group attempted to explain the variability in paclitaxel exposure by utilizing separate
probes for each enzyme. We reported for the first time that rosiglitazone may have value as
an in vivo probe of CYP2C8 activity; a single concentration of rosiglitazone at 3 h explained
approximately 38% of the variability in paclitaxel AUC0–6 h (p = 0.018), however, the
inclusion of ERMBT as a CYP3A probe did not meaningfully contribute to the explanation
of the variability in paclitaxel exposure [96].
Relationship between probes & clinical outcome
There is reasonable evidence of a relationship between CYP3A probes and docetaxel PK,
however, the association between the probe and clinical outcome has not been as
comprehensively documented [86,95,97]. In one study the antipyrine disappearance rate
correlated with neutrophil nadir and risk of grade 3+ neutropenia [97]. In the previously
mentioned prospective study of cortisol metabolite-based dosing, nominally fewer patients
in the individualized dosing arm experienced grade 3–4 neutropenia when compared with
the BSA-based dosing arm (86 vs 93%), though the small magnitude of effect suggests that
this may not be a clinically useful approach for preventing neutropenia [95].
Challenges of enzyme probes
In most cases the PK of a drug is determined not by a single enzyme, but by the interplay of
a variety of factors such as enzymes, transporters and formulation vehicles. For instance,
both taxanes are substrates for a variety of uptake (OATP1B3) [15,16] and efflux (P-gp)
transporters [20,21]. The influence of these transporters on the results of probe assays has
only been recently recognized and is not well characterized [31,98]. In addition, the vehicle
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Cremophor® EL (BASF Corp., Ludwigshafen, Germany) might interfere with the ability of
probes to estimate paclitaxel metabolism since Cremophor EL influences the unbound
paclitaxel concentration [99], but further research is required to assess this possible effect.
Another challenge for the development of enzyme probes is substrate dependence, the idea
that a change in the enzyme–substrate interaction or the system within which the interaction
takes place will not have a consistent effect on the probe and the drug of interest. For
example, imatinib, a CYP3A4 inhibitor, decreases ERMBT-estimated CYP3A activity but
does not change docetaxel clearance [100]. Substrate dependency has also been reported in
relation to certain genotypes, such as CYP2C8*3, which was described as a low-activity
variant in the previous section, but seems to have increased activity toward other substrates,
including rosiglitazone [101] and pioglitazone [102]. The influence of transporters,
supplementary metabolic pathways, and substrate dependence may explain the lack of
correlation seen when patients are administered multiple probes of the same enzyme [103].
If an enzyme probe that accurately predicts in vivo taxane exposure is validated, logistical
challenges to clinical implementation will still exist. Sample collection and analysis,
particularly for the ERMBT which requires specialized collection equipment, will introduce
new costs to the healthcare system and potential inconvenience to patients. Each potential
probe has specific challenges but the overall benefit of a validated probe that could
accurately predict taxane exposure is likely to outweigh these limitations and have
widespread clinical utility.
Future work for enzyme probes
The existing studies suggest that an in vivo probe may explain a significant portion of the
interindividual variability in taxane PK. There is more work to be done to translate enzyme
probes to clinical application, starting with determination of the probe that best reflects the
PK of each taxane. Once the optimal probe is identified, prospective studies are needed to
verify the a priori improvement in taxane dose selection from probe usage. Then,
prospective studies comparing therapeutic outcomes using probe versus BSA-based dosing
are needed to validate the clinical utility of enzyme probes, and the costs of this approach
must be weighed against these benefits, particularly in subgroups of patients in whom
empirical dose selection is challenging.
TDM
TDM is an approach to individualizing therapy that employs systematic drug-level
monitoring to adjust future dosages. TDM enables targeting of an exposure level in order to
improve the likelihood of response, minimize the probability of toxicity, or both. In general,
TDM is considered useful for drugs that have shown extensive PK variability, a narrow
therapeutic window and a well-defined relationship between systemic exposure (PK) and
toxicity or response (pharmacodynamics [PD]) [104,105]. Most of the current anticancer
drugs, including taxanes, meet the first two criteria [104], but it is challenging to define a
drug’s PK–PD relationship. Over the last 10 years, tremendous progress has been made in
describing the PK–PD for taxanes. In this section we will briefly review these PK–PD
relationships and describe the potential and challenges of using TDM as a tool for
individualizing docetaxel or paclitaxel therapy.
Docetaxel
PK–PD relationship—The toxicity profile of docetaxel is predominately hematological,
with other less common toxicities including fluid retention and neuropathy. Several studies
have reported a relationship between docetaxel PK parameters, particularly clearance or
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AUC, and these toxicities [23,25,106-111]. Our understanding of the relationship between
docetaxel PK and treatment efficacy is more limited with only a few studies demonstrating
an association between PK and progression or survival (Table 3) [23,25,106].
Clinical attempts at TDM—Only one published study has explored the potential for
individualizing docetaxel dosing through TDM [112]. Engels et al. utilized a limited PK
sampling strategy and a validated population PK model with a predefined target AUC of 4.9
mg/l × h. Fifteen patients were treated with at least one course of PK-guided docetaxel and
were compared with a group of 15 patients receiving conventional (BSA-based) docetaxel
therapy. TDM-guided dosing resulted in a decrease in interindividual variability (standard
deviation of natural log-transformed AUC) of 39%; somewhat lower than the study’s
predefined objective of a 50% decrease. Even though the differences in percentage decrease
in white blood cell or absolute neutrophil count were also not statistically significant, PK-
guided dosing successfully decreased the interindividual variability in these measures by
approximately 50%. Despite the lack of statistical significance, this small study suggests that
AUC-targeted dosing may attenuate the interindividual variability in drug exposure and
hematological toxicity, and demonstrates the clinical feasibility of docetaxel TDM with
limited PK sampling.
Paclitaxel
PK–PD relationships—Numerous studies have found a relationship between paclitaxel
exposure and toxicity [113-122] or efficacy (Table 4) [116,118,123]. Based on these studies
the most important parameter of paclitaxel PK seems to be the time that the systemic
concentration remains above a threshold of 0.05 or 0.1 μM. This parameter has been
associated with a variety of adverse events, such as neutropenia and neuropathy, and
measures of treatment effectiveness.
Clinical attempts at TDM—Woo et al. reported the initial attempt at utilizing paclitaxel
TDM, targeting a range for systemic exposure in seven children with recurrent acute
leukemia receiving 24-h infusions [124]. In this single-arm study the infusion rate was
adjusted based on clearance estimated 8 h into infusion. Five of the seven children reached
AUCs between 75 and 125% of the target, whereas none were projected to reach target AUC
without adjustment, demonstrating that adjusting the paclitaxel dose based on a target AUC
range is clinically feasible for a 24-h infusion. In another study de Jonge et al. targeted a
paclitaxel threshold of >0.1 μM for ≥15 h in 25 non-small-cell lung cancer patients [125]. In
the first cycle a standard regimen of 175 mg/m2 was given to all patients and subsequent
doses were adjusted based on their time above threshold. In the first cycle more than one-
third of the patients (nine out of 25; 36%) had suboptimal exposure, but using TDM this
decreased to 23% (five out of 22) and 11% (one out of nine) by cycles 2 and 6, respectively.
Challenges of TDM
The previously described studies demonstrate that taxane TDM is clinically feasible.
However, there are serious challenges to its widespread implementation. TDM requires the
development of an assay for the drug of interest that quickly returns accurate results. As
with the other techniques described, TDM will introduce new healthcare costs by requiring
collection and analysis of patient samples, and highly trained staff to interpret the PK results
and recommend appropriate dose adjustments. It could also be burdensome on the patient,
who will need to remain at the treatment center or return to the facility for sample collection.
However, these challenges have been overcome in other therapeutic areas such as infectious
disease or neurology, both of which employ TDM in certain treatment situations.
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Future work for TDM
Pilot studies of the use of TDM suggest that this approach is clinically feasible and can
successfully limit taxane interindividual variability or enable clinicians to target specific
parameters of drug exposure. Though the connection between taxane exposure and treatment
outcome has been an area of rich investigation, additional research is needed to more
explicitly define these PK–PD relationships. Application of this developing knowledge will
facilitate the design and execution of prospective TDM studies. One approach to this,
reported recently by Joerger et al., is to perform PK–PD simulations to establish TDM-based
dosing algorithms and estimate the clinical benefit of implementation [126]. Their proposed
algorithm was simulated in 1000 patients and resulted in a reduction of grade 4 neutropenia
in cycle 1 from 15 to 7%, and a further reduction to 4% in cycle 2. These simulations could
assist in the design of large, prospective studies to compare TDM and empirical dosing with
the primary aim of demonstrating an improvement in relevant clinical outcomes. The cost–
effectiveness of TDM will also need to be considered before clinical uptake of TDM for
taxane therapy is realized.
Conclusion
This article examined the potential use of pharmacogenetics, enzyme probes and TDM as
tools for individualizing taxane therapy. Of the three approaches, TDM may, when ready for
implementation, have the greatest value for clinical practice. Until then, pharmacogenetics
and enzyme probes could assist in treatment decision-making in the near future. All three
tools require continued validation and prospective studies with predefined, clinically
relevant end points and robust statistical power, in addition to recognition of the added costs
and potential inconvenience of clinical implementation.
It is important to note that these tools are not mutually exclusive; ultimately taxane
treatment may incorporate elements of each approach into an adaptive treatment paradigm
centered on the individual patient (Figure 2). Pharmacogenetics, in parallel with our rapidly
advancing ability to select drugs based on tumor characteristics [127,128], could be used to
select patients most likely to benefit or least likely to experience severe toxicity for
treatment with a taxane. An enzyme probe could then be combined with other patient
characteristics known to influence taxane exposure, such as age, gender and bilirubin levels,
in order to design an initial dosing regimen for that patient [11,129]. Finally, TDM could
guide iterative dose adjustment to ensure the patient’s taxane exposure is optimized. After
20 years of experience with taxanes in clinical practice it is time to look beyond BSA-based
dosing and utilize the available tools to establish a revolutionary, individualized taxane
treatment paradigm, ushering in the long-awaited era of personalized cancer therapy.
Future perspective
The one-size-fits-all approach to taxane dosing, which almost exclusively uses the patient’s
BSA to determine what dose they will receive throughout their course of treatment, will
eventually be replaced by an individualized, adaptive dosing scheme. The SNPs that
appreciably influence a patient’s likelihood of response or toxicity will be used in
conjunction with somatic genetic information to screen out patients who are likely to
experience suboptimal treatment outcomes. Initial doses of taxanes will be estimated using
complex algorithms that combine standard patient factors with in vivo assays that predict
drug exposure. Actual exposure will be monitored during treatment to enable adjustment of
subsequent doses to achieve target concentrations that maximize patient outcomes. Initial
validation and translation of these tools will likely be limited to specific treatment settings,
but ultimately these incremental steps will coalesce into a revolutionary treatment paradigm
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that deploys these complementary tools to maximize efficacy and minimize toxicity of
taxane treatment.
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■ Taxane dosing is primarily based on body surface area, but this does not
reduce the large interindividual variability in pharmacokinetics and
unpredictability of treatment response and toxicity.
■ Tools that have been used to individualize treatment with other drugs, such as
pharmacogenetics, enzyme probes and therapeutic drug monitoring, are being
investigated for their potential role in taxane treatment.
■ This article highlights the progress and potential for each tool and the
challenges and next steps for clinical translation.
Pharmacogenetics
■ Variants in genes relevant to pharmacology or biology may influence a
patient’s response to therapy or risk of side effects.
■ Numerous studies have been published on associations between
pharmacogenetic variants and taxane treatment outcomes, with highly
inconsistent results.
■ Some associations have been consistently replicated in multiple independent
patient populations (CYP3A5*3, CYP2C8*3, ABCB1*2 and CYP1B1*3),
suggesting that there may be a true association between the variant and
treatment outcome.
■ These variants should be prioritized for validation in large patient cohorts,
followed by prospective evaluation of genotype-guided taxane treatment.
Enzyme probes
■ Drug exposure is largely determined by the activity of metabolic enzymes.
■ Enzyme probes may be able to estimate the in vivo activity of the enzyme of
interest, enabling selection of an appropriate dose to achieve a target
exposure.
■ Multiple CYP3A probes (erythromycin breath test, antipyrine and cortisol)
have demonstrated an in vivo correlation with docetaxel pharmacokinetics.
■ Rosiglitazone is the only CYP2C8 probe that has been reported to have an in
vivo correlation with paclitaxel pharmacokinetics.
■ Translation of a probe into clinical practice will require prospective
confirmation that probe-based dosing confers a clinically relevant benefit.
Therapeutic drug monitoring
■ The taxanes have high interindividual pharmacokinetic variability and a
narrow therapeutic window, making them ideal for therapeutic drug
monitoring.
■ Pharmacokinetic–pharmacodynamic studies have demonstrated that certain
parameters of drug exposure are associated with likelihood of toxicity or
efficacy from taxane therapy.
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■ Therapeutic drug monitoring has been piloted for both docetaxel and
paclitaxel, demonstrating clinical feasibility and success in achieving targets
of drug exposure.
■ Prospective evaluation of the benefit of therapeutic drug monitoring is
necessary before widespread adoption into clinical use.
Conclusion
■ The three tools outlined in this article have great potential for improving
taxane treatment; however, none are ready for clinical implementation at this
time.
■ Each will need to improve patient outcomes in large, well-designed
prospective studies before integration into standard clinical practice.
■ The benefit to patients will need to be balanced with the additional expense
and potential for patient inconvenience when determining the clinical role for
each tool.
■ In the future these three tools will be used complementarily to individualize
each patient’s taxane treatment to maximize efficacy and limit toxicity.
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Figure 1. Intracellular metabolism of docetaxel and paclitaxel
Dashed lines indicate passive diffusion. The short series of arrows before the formation of
the docetaxel metabolites (M1, M2, M3 and M4) designates the possible involvement of
multiple enzyme reactions not presented in this figure.
6αOH-pac: 6α-hydroxypaclitaxel; diOH-pac: 6α-p-3′-dihydroxypaclitaxel; p3OH-pac: p-3′-
hydroxypaclitaxel.
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Figure 2. Integrated approach to taxane treatment that utilizes pharmacogenetics, enzyme
probes and therapeutic drug monitoring to enhance efficacy and limit toxicity of therapy for
cancer patients
These tools can help screen out patients who are not good candidates for taxane treatment,
assist in estimating a starting dose for taxane-treated patients and enable ongoing
optimization of taxane dosing throughout treatment.
BSA: Body surface area in mg/m2.
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